Pause over an offer that skips the basics

Prescription drugs need a valid prescriber’s order, under federal law checked November 3, 2026. Dispensing one without that order makes it legally misbranded: here, that means the prescription requirement was broken, not that the drug has the wrong brand name.

Ask how the assessment works and who is responsible for it. If an offer jumps from a product menu to payment, ask where the clinical conversation fits. Do not treat a checkout screen as an explanation of that process.

The national association for doctor-licensing boards rejects care based just on a person’s treatment selection on a website. This association is the Federation of State Medical Boards. This guidance dates from May 2026 and was checked November 3, 2026.

That guidance also calls for access to the clinician, the health professional providing care, for later questions; it offers advice to boards, and state law still supplies the binding rules.

In warning letters reviewed November 3, 2026, the Food and Drug Administration (FDA) saw claims about use in people and supplies for preparing injections as signs that the products were meant to be drugs, despite research-only wording on the product.

A warning letter gives the agency’s allegations about a particular firm. It is not a court judgment. The useful reading habit is to compare the small label with what the rest of the page says the product will do.

If the explanation relies entirely on a label while the sales copy makes treatment claims, keep that inconsistency in view. Ask what law or FDA approval allows that specific product to be supplied. A different label is not an answer to that question.

Establishment registration puts a drug business’s location on FDA’s records. Drug listing puts its products on those records. Neither gives FDA approval or permission to market a product, in the federal regulation reviewed on November 3, 2026.

For compounded products, FDA’s guidance checked November 3, 2026 says it is misleading to claim they are the same as an approved medicine or have FDA approval.

The FDA guidance on compounded-drug advertising separates those claims from the product’s real status.

Ask what a badge or number actually establishes. Keep the product question separate from the license question. If the explanation keeps switching between them, ask for a direct answer about each. The state record check gives the licensing question its own place.

The FDA consumer checklist recorded September 17, 2026 flags missing post-delivery access to a doctor, questionable pharmacy details, and claims that a compounded medicine matches an approved one.

Use the FDA’s consumer questions to examine the offer as a whole.

Ask who would answer a question after medicine arrives. Ask which pharmacy supplies it and how that name can be checked. Keep the replies, rather than relying on a general promise of support.

There is no need to settle every concern while a payment page is open. Save the questions in your own notes and take them to the named clinician or pharmacy. The question desk helps turn the unclear parts into short, direct requests for an answer.